Barclays
JNCE

Barclays’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Barclays’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-81,800
Closed -$1.83M – 7401
2018
Q1 		$1.83M Buy
+81,800
New +$1.82M ﹤0.01% 2551

Other funds holding JNCE

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Barclays's JNCE Position: Q2 2023 in Review

Barclays sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 21,498 shares — an estimated $39.8K sold.

Barclays first reported a position in JNCE in Q1 2017 and held it in 25 quarters. The position peaked at $6M in Q4 2021. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

  • Barclays reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Barclays sold 21,498 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $39.8K.
  • Barclays first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 25 quarters.
  • Barclays's Jounce Therapeutics, Inc. Common Stock position peaked at $6M in Q4 2021.
  • 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Barclays's 13F filing for Q2 2023, filed 3 Aug 2023.